67 related articles for article (PubMed ID: 748047)
1. The response of plasma somatostatin-like immunoreactivity to nutrients in normal and alloxan diabetic dogs.
Schusdziarra V; Rouiller D; Harris V; Conlon JM; Unger RH
Endocrinology; 1978 Dec; 103(6):2264-73. PubMed ID: 748047
[No Abstract] [Full Text] [Related]
2. Origin of peripheral venous hypersomatostatinemia in alloxan-diabetic dogs.
Schusdziarra V; Rouiller D; Harris V; Unger RH
Endocrinology; 1981 Oct; 109(4):1107-16. PubMed ID: 6116595
[TBL] [Abstract][Full Text] [Related]
3. Response of plasma somatostatin-like immunoreactivity to the administration of alloxan in dogs.
Schusdziarra V; Harris V; Unger R
Horm Metab Res; 1979 Aug; 11(8):457-9. PubMed ID: 499995
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactive somatostatin levels in plasma of normal and alloxan diabetic dogs.
Schusdziarra V; Dobbs RE; Harris V; Unger RH
FEBS Lett; 1977 Sep; 81(1):69-72. PubMed ID: 332526
[No Abstract] [Full Text] [Related]
5. Paradoxical reduction in pancreatic glucagon with normalization of somatostatin and decrease in insulin in normoglycemic alloxan-diabetic dogs: a putative mechanism of glucagon irresponsiveness to hypoglycemia.
Rastogi KS; Lickley L; Jokay M; Efendic S; Vranic M
Endocrinology; 1990 Feb; 126(2):1096-104. PubMed ID: 1967577
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a role of free fatty acids in the regulation of somatostatin secretion in normal and alloxan diabetic dogs.
Wasada T; Howard B; Dobbs RE; Unger RH
J Clin Invest; 1980 Sep; 66(3):511-6. PubMed ID: 6105166
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogs as glucagon suppressants in diabetes.
Schusdziarra V; Rivier J; Dobbs R; Brown M; Vale W; Unger R
Horm Metab Res; 1978 Nov; 10(6):563-5. PubMed ID: 744579
[No Abstract] [Full Text] [Related]
8. Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized, and alloxan-diabetic dogs.
Valverde I; Dobbs R; Unger RH
Metabolism; 1975 Sep; 24(9):1021-8. PubMed ID: 1152674
[TBL] [Abstract][Full Text] [Related]
9. The influence of endogenous glucagon release on hyperglycemic responses to catecholamines in normal fed and diabetic rats.
Woodson LC; Potter DE
J Pharmacol Exp Ther; 1979 Sep; 210(3):458-64. PubMed ID: 480194
[TBL] [Abstract][Full Text] [Related]
10. Dynamic time-course studies of the spontaneously diabetic BB Wistar rat. II. Insulin-, glucagon-, and somatostatin-reactive cells in the pancreas.
Tannenbaum GS; Colle E; Wanamaker L; Gurd W; Goldman H; Seemayer TA
Endocrinology; 1981 Dec; 109(6):1880-7. PubMed ID: 6118255
[No Abstract] [Full Text] [Related]
11. [Paradoxical hyperglucagonemia after oral administration of glucose in diabetic dogs. Impact of the cholinergic nervous system].
Hillaire-Buys D; Ribes G; Gross R; Loubatières-Mariani MM
C R Seances Soc Biol Fil; 1987; 181(6):677-82. PubMed ID: 2970286
[TBL] [Abstract][Full Text] [Related]
12. Effect of a zinc phosphate suspension of a long-acting somatostatin analog on postprandial plasma glucose, triglyceride and glucagon concentrations in alloxan diabetic dogs.
Martin C; Wallum B; Krom B; Hall L; Gerich J
Life Sci; 1984 Dec; 35(26):2627-33. PubMed ID: 6151111
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone and somatostatin in the plasma of transiently diabetic ducks: basal variation and response to glucose.
Laurent F; Karmann H; Harvey S; Foltzer C; Mialhe P
Gen Comp Endocrinol; 1989 May; 74(2):181-9. PubMed ID: 2565851
[TBL] [Abstract][Full Text] [Related]
14. [Effects of beta-selective blockade on levels of glucagon in blood plasma during insulin-induced hypoglycemia].
Szelachowska M; Kinalska I
Pol Tyg Lek; 1989 May 22-29; 44(21-22):488-91. PubMed ID: 2702337
[TBL] [Abstract][Full Text] [Related]
15. Morphine-induced hyperglycemia: role of insulin and glucagon.
Ipp E; Schusdziarra V; Harris V; Unger RH
Endocrinology; 1980 Aug; 107(2):461-3. PubMed ID: 6993188
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of stress induced hyperglucagonemia by administration of glucose in normal and alloxan-diabetic rat.
Klimes I; Jurcovicová J; Németh S; Jezová D; Vigas M
Endocrinol Exp; 1981; 15(2):87-97. PubMed ID: 7021127
[TBL] [Abstract][Full Text] [Related]
17. Release of somatostatin-like immunoreactivity from the lower gut.
Rouiller D; Schusdziarra V; Conlon JM; Harris V; Unger RH
Gastroenterology; 1979 Oct; 77(4 Pt 1):700-3. PubMed ID: 467926
[TBL] [Abstract][Full Text] [Related]
18. Evidence for a role of splanchnic somatostatin in the homeostasis of ingested nutrients.
Schusdziarra V; Harris V; Arimura A; Unger RH
Endocrinology; 1979 Jun; 104(6):1705-8. PubMed ID: 446390
[TBL] [Abstract][Full Text] [Related]
19. Effects of insulin on fasting and meal-stimulated somatostatin-like immunoreactivity in noninsulin-dependent diabetes mellitus: evidence for more than one mechanism of action.
Gutniak M; Grill V; Efendić S
J Clin Endocrinol Metab; 1986 Jan; 62(1):77-83. PubMed ID: 2866196
[TBL] [Abstract][Full Text] [Related]
20. Treatment of streptozotocin-diabetic dogs with a long-acting somatostatin analog.
Lien EL; Greenwood J; Sarantakis D
Diabetes; 1979 May; 28(5):491-5. PubMed ID: 437379
[No Abstract] [Full Text] [Related]
[Next] [New Search]
